JP5711814B2 - キナーゼ阻害剤の結晶形態 - Google Patents
キナーゼ阻害剤の結晶形態 Download PDFInfo
- Publication number
- JP5711814B2 JP5711814B2 JP2013514330A JP2013514330A JP5711814B2 JP 5711814 B2 JP5711814 B2 JP 5711814B2 JP 2013514330 A JP2013514330 A JP 2013514330A JP 2013514330 A JP2013514330 A JP 2013514330A JP 5711814 B2 JP5711814 B2 JP 5711814B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- thieno
- amino
- hydroxyethyl
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Description
N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素遊離塩基形態IまたはIIおよび1つ以上の医薬として許容される賦形剤を含む医薬組成物がさらに提供される。
N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素遊離塩基固体(100mg)を、THF/水混合物(80/20体積比、500μL)中に懸濁させた。周囲温度での3日間の平衡の後、遠心濾過によって固体を集めた。
N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素遊離塩基形態I一水和物固体(10mg)を130℃で脱水した。脱水後新たな多形の無水の遊離塩基が観察された。
Claims (10)
- 結晶形態が、粉末X線回折ピークが以下の位置:7.20、8.37、11.38、16.75、16.95、19.60、22.04、および22.86°の2θ(±0.2° 2θ)のそれぞれにあることを少なくとも特徴とする、形態Iの遊離塩基である、固体結晶形態である化合物N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素。
- 結晶形態が、粉末X線回折ピークが以下の位置:4.36、7.20、8.37、11.38、14.40、14.86、15.02、16.75、16.95、19.60、21.66、22.04、22.31、および22.86°の2θ(±0.2° 2θ)のそれぞれにあることを少なくとも特徴とする、形態Iの遊離塩基である、固体結晶形態である化合物N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素。
- 結晶形態が、一水和物である、請求項1または2に記載の化合物。
- 請求項1から3のいずれかに記載の化合物および1つまたは複数の医薬として許容される賦形剤を含む医薬組成物。
- a)(i)完全に助溶剤内に溶解している、N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素、水およびテトラヒドロフランを含む混合物を準備するステップ、
b)N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素の結晶形態Iを前記混合物中に生じさせるステップ、
を含む、結晶形態が請求項1から3のいずれかに記載の形態Iの遊離塩基である固体結晶形態のN−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素を調製する方法。 - 結晶形態が形態Iの遊離塩基である、固体結晶形態のN−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素を単離するステップをさらに含む、請求項5に記載の方法。
- 結晶形態が、粉末X線回折ピークが以下の位置:7.30、8.81、11.32、15.08、16.79、19.46、22.22、22.70、23.37、24.29、24.61、25.07°の2θ(±0.2° 2θ)のそれぞれにあることを少なくとも特徴とする、形態IIの遊離塩基である、固体結晶形態の化合物N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素。
- 結晶形態が、粉末X線回折ピークが以下の位置:4.51、7.30、8.39、8.81、11.32、14.63、15.08、15.82、16.79、19.46、22.22、22.70、23.37、24.29、24.61、25.07°の2θ(±0.2° 2θ)のそれぞれにあることを少なくとも特徴とする、形態IIの遊離塩基である、固体結晶形態の化合物N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素。
- 請求項7または8に記載の化合物および1つまたは複数の医薬として許容される賦形剤を含む医薬組成物。
- a)(i)N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素遊離塩基の形態Iの一水和物を準備するステップ、および
b)N−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素遊離塩基の形態Iの一水和物を脱水するステップ、
を含む、結晶形態が請求項7または8に記載の形態IIの遊離塩基である、固体結晶形態のN−(4−{4−アミノ−7−[1−(2−ヒドロキシエチル)−1H−ピラゾール−4−イル]チエノ[3,2−c]ピリジン−3−イル}フェニル)−N’−(3−フルオロフェニル)尿素を調製する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35305810P | 2010-06-09 | 2010-06-09 | |
US61/353,058 | 2010-06-09 | ||
PCT/US2011/039582 WO2011156461A1 (en) | 2010-06-09 | 2011-06-08 | Crystalline forms of kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013528220A JP2013528220A (ja) | 2013-07-08 |
JP5711814B2 true JP5711814B2 (ja) | 2015-05-07 |
Family
ID=44454740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013514330A Expired - Fee Related JP5711814B2 (ja) | 2010-06-09 | 2011-06-08 | キナーゼ阻害剤の結晶形態 |
Country Status (18)
Country | Link |
---|---|
US (2) | US8357804B2 (ja) |
EP (1) | EP2580219B1 (ja) |
JP (1) | JP5711814B2 (ja) |
KR (1) | KR20130112855A (ja) |
CN (1) | CN103025741A (ja) |
AR (1) | AR083722A1 (ja) |
AU (1) | AU2011264899B2 (ja) |
BR (1) | BR112012031469A2 (ja) |
CA (1) | CA2802064A1 (ja) |
ES (1) | ES2537708T3 (ja) |
HK (1) | HK1182384A1 (ja) |
MX (1) | MX2012014385A (ja) |
NZ (1) | NZ605436A (ja) |
RU (1) | RU2012157471A (ja) |
SG (1) | SG186249A1 (ja) |
TW (1) | TWI492949B (ja) |
WO (1) | WO2011156461A1 (ja) |
ZA (1) | ZA201209647B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202110406SA (en) | 2019-04-11 | 2021-10-28 | Angion Biomedica Corp | Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
GB0402518D0 (en) * | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
US20070135387A1 (en) * | 2005-12-08 | 2007-06-14 | Michaelides Michael R | Inhibitors of protein kinases |
EP2262815A4 (en) * | 2008-03-05 | 2012-04-11 | Methylgene Inc | Inhibitors of protein intolerance activity |
TWI441827B (zh) | 2008-12-05 | 2014-06-21 | Abbvie Bahamas Ltd | 具改良cyp安全性之激酶抑制劑 |
-
2011
- 2011-06-07 TW TW100119846A patent/TWI492949B/zh not_active IP Right Cessation
- 2011-06-08 KR KR1020137000509A patent/KR20130112855A/ko not_active Application Discontinuation
- 2011-06-08 RU RU2012157471/04A patent/RU2012157471A/ru not_active Application Discontinuation
- 2011-06-08 ES ES11726595.9T patent/ES2537708T3/es active Active
- 2011-06-08 EP EP11726595.9A patent/EP2580219B1/en not_active Not-in-force
- 2011-06-08 SG SG2012090528A patent/SG186249A1/en unknown
- 2011-06-08 AU AU2011264899A patent/AU2011264899B2/en not_active Ceased
- 2011-06-08 BR BR112012031469A patent/BR112012031469A2/pt not_active IP Right Cessation
- 2011-06-08 JP JP2013514330A patent/JP5711814B2/ja not_active Expired - Fee Related
- 2011-06-08 CA CA2802064A patent/CA2802064A1/en not_active Abandoned
- 2011-06-08 NZ NZ605436A patent/NZ605436A/en not_active IP Right Cessation
- 2011-06-08 MX MX2012014385A patent/MX2012014385A/es active IP Right Grant
- 2011-06-08 WO PCT/US2011/039582 patent/WO2011156461A1/en active Application Filing
- 2011-06-08 CN CN2011800377568A patent/CN103025741A/zh active Pending
- 2011-06-09 US US13/156,520 patent/US8357804B2/en not_active Expired - Fee Related
- 2011-06-09 AR ARP110101991A patent/AR083722A1/es unknown
-
2012
- 2012-12-17 US US13/717,246 patent/US8592589B2/en not_active Expired - Fee Related
- 2012-12-19 ZA ZA2012/09647A patent/ZA201209647B/en unknown
-
2013
- 2013-08-20 HK HK13109691.8A patent/HK1182384A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201204736A (en) | 2012-02-01 |
US8357804B2 (en) | 2013-01-22 |
CN103025741A (zh) | 2013-04-03 |
RU2012157471A (ru) | 2014-07-20 |
WO2011156461A1 (en) | 2011-12-15 |
EP2580219B1 (en) | 2015-02-25 |
US20120149726A1 (en) | 2012-06-14 |
MX2012014385A (es) | 2013-05-01 |
ES2537708T3 (es) | 2015-06-11 |
SG186249A1 (en) | 2013-01-30 |
CA2802064A1 (en) | 2011-12-15 |
NZ605436A (en) | 2014-11-28 |
AU2011264899B2 (en) | 2015-01-22 |
BR112012031469A2 (pt) | 2016-11-01 |
US8592589B2 (en) | 2013-11-26 |
KR20130112855A (ko) | 2013-10-14 |
HK1182384A1 (en) | 2013-11-29 |
JP2013528220A (ja) | 2013-07-08 |
EP2580219A1 (en) | 2013-04-17 |
AU2011264899A1 (en) | 2013-01-10 |
TWI492949B (zh) | 2015-07-21 |
AR083722A1 (es) | 2013-03-20 |
US20130136804A1 (en) | 2013-05-30 |
ZA201209647B (en) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5727599B2 (ja) | キナーゼ阻害剤の結晶形態 | |
JP5711814B2 (ja) | キナーゼ阻害剤の結晶形態 | |
JP5727598B2 (ja) | キナーゼ阻害剤の結晶形 | |
US20170197980A1 (en) | N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate | |
WO2013090666A1 (en) | Compositions containing kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141111 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150306 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5711814 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |